{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:48:42Z","timestamp":1792648122240,"version":"4.5.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1097\/mpa.0b013e3181ebb2a5","type":"journal-article","created":{"date-parts":[[2010,7,21]],"date-time":"2010-07-21T07:10:36Z","timestamp":1279696236000},"page":"753-766","source":"Crossref","is-referenced-by-count":473,"title":["The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors"],"prefix":"10.1097","volume":"39","author":[{"given":"J. Philip","family":"Boudreaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Klimstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal M.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene A.","family":"Woltering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley J.","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Nutting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Bushnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn E.","family":"Caplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210212","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R2-5-20210212","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jso.2930060503","article-title":"2nd. The epidemiologic pathology of carcinomas of the large bowel.","volume":"6","author":"Berg","year":"1974","journal-title":"J Surg Oncol"},{"key":"R3-5-20210212","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/1097-0142(196109\/10)14:5<901::AID-CNCR2820140502>3.0.CO;2-Q","article-title":"Life history of the carcinoid tumor of the small intestine.","volume":"14","author":"Moertel","year":"1961","journal-title":"Cancer"},{"key":"R5-5-20210212","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/1055-9965.EPI-07-0750","article-title":"Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study.","volume":"17","author":"Hassan","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R6-5-20210212","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/annonc\/mdn706","article-title":"Familial gastrointestinal carcinoid tumours and associated cancers.","volume":"20","author":"Hiripi","year":"2009","journal-title":"Ann Oncol"},{"key":"R7-5-20210212","first-page":"205","article-title":"Risk factors for adenocarcinomas and malignant carcinoids of the small intestine: preliminary findings.","volume":"3","author":"Chen","year":"1994","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R8-5-20210212","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF00053158","article-title":"Risk factors for small intestine cancer.","volume":"4","author":"Chow","year":"1993","journal-title":"Cancer Causes Control"},{"key":"R9-5-20210212","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1013922226614","article-title":"The importance of smoking and medical history for development of small bowel carcinoid tumor: a European population-based case-control study.","volume":"13","author":"Kaerlev","year":"2002","journal-title":"Cancer Causes Control"},{"key":"R10-5-20210212","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/ijc.23529","article-title":"Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study.","volume":"123","author":"Hassan","year":"2008","journal-title":"Int J Cancer"},{"key":"R11-5-20210212","doi-asserted-by":"crossref","first-page":"9274","DOI":"10.1158\/0008-5472.CAN-08-2015","article-title":"A prospective study of meat and fat intake in relation to small intestinal cancer.","volume":"68","author":"Cross","year":"2008","journal-title":"Cancer Res"},{"key":"R12-5-20210212","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1053\/j.gastro.2008.07.015","article-title":"Prospective study of dietary fiber, whole grain foods, and small intestinal cancer.","volume":"135","author":"Schatzkin","year":"2008","journal-title":"Gastroenterology"},{"key":"R13-5-20210212","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/PAS.0b013e31817f1816","article-title":"Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix.","volume":"32","author":"Tang","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R14-5-20210212","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/(SICI)1096-9896(200001)190:1<76::AID-PATH499>3.0.CO;2-1","article-title":"Clonality analysis of multifocal carcinoid tumours of the small intestine by X-chromosome inactivation analysis.","volume":"190","author":"Guo","year":"2000","journal-title":"J Pathol"},{"key":"R15-5-20210212","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/modpathol.3800825","article-title":"Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors).","volume":"20","author":"Choi","year":"2007","journal-title":"Mod Pathol"},{"key":"R16-5-20210212","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/(SICI)1522-2586(200002)11:2<141::AID-JMRI10>3.0.CO;2-U","article-title":"Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI.","volume":"11","author":"Semelka","year":"2000","journal-title":"J Magn Reson Imaging"},{"key":"R17-5-20210212","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.mric.2005.03.012","article-title":"MR imaging of the pancreas.","volume":"13","author":"Pamuklar","year":"2005","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"R18-5-20210212","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s003300050221","article-title":"MRI of pancreatic tumors.","volume":"7","author":"Kelekis","year":"1997","journal-title":"Eur Radiol"},{"key":"R19-5-20210212","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2214\/ajr.180.1.1800121","article-title":"MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques.","volume":"180","author":"Dromain","year":"2003","journal-title":"Am J Roentgenol"},{"key":"R20-5-20210212","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1259\/bjr.74.887.741065","article-title":"Imaging appearances of metastases from neuroendocrine tumours of the pancreas.","volume":"74","author":"Debray","year":"2001","journal-title":"Br J Radiol"},{"key":"R21-5-20210212","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","article-title":"Radiotherapy with a radiolabeled somatostatin analogue, 111In-DTPA-D-Phe1-octreotide.","volume":"733","author":"Krenning","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"R22-5-20210212","first-page":"1134","article-title":"Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.","volume":"42","author":"Balon","year":"2001","journal-title":"J Nucl Med"},{"key":"R23-5-20210212","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1210\/jc.2004-1938","article-title":"Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography.","volume":"90","author":"Orlefors","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-5-20210212","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1470::AID-CNCR7>3.0.CO;2-S","article-title":"Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas.","volume":"85","author":"Goebel","year":"1999","journal-title":"Cancer"},{"key":"R25-5-20210212","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1054\/bjoc.2000.1659","article-title":"A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.","volume":"84","author":"Bernini","year":"2001","journal-title":"Br J Cancer"},{"key":"R26-5-20210212","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2265.2004.02030.x","article-title":"Interest of chromogranin A for diagnosis and follow-up of endocrine tumours.","volume":"60","author":"Nehar","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R27-5-20210212","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8","article-title":"Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.","volume":"86","author":"Bajetta","year":"1999","journal-title":"Cancer"},{"key":"R28-5-20210212","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/pgmj.71.839.542","article-title":"The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid.","volume":"71","author":"Tormey","year":"1995","journal-title":"Postgrad Med J"},{"key":"R29-5-20210212","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/ajcn\/42.4.639","article-title":"Serotonin content of foods: effect on urinary excretion of 5-hydroxyindoleacetic acid.","volume":"42","author":"Feldman","year":"1985","journal-title":"Am J Clin Nutr"},{"key":"R30-5-20210212","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors.","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"key":"R31-5-20210212","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/02841860410018502","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview.","volume":"43","author":"Oberg","year":"2004","journal-title":"Acta Oncol"},{"key":"R32-5-20210212","first-page":"40","article-title":"A gastric carcinoid tumor with massive bleeding.","volume":"61","author":"Honig","year":"1974","journal-title":"Am J Gastroenterol"},{"key":"R33-5-20210212","first-page":"1118","article-title":"Perianesthetic risks and outcomes of pheochromocytoma and paraganglioma resection.","volume":"91","author":"Kinney","year":"2000","journal-title":"Anesth Analg"},{"key":"R34-5-20210212","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF03010865","article-title":"Pre-treatment with somatostatin in the anaesthetic management of a patient with carcinoid syndrome.","volume":"35","author":"Parris","year":"1988","journal-title":"Can J Anaesth"},{"key":"R35-5-20210212","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1213\/00000539-199402000-00032","article-title":"Intraoperative octreotide for refractory carcinoid-induced bronchospasm.","volume":"78","author":"Quinlivan","year":"1994","journal-title":"Anesth Analg"},{"key":"R36-5-20210212","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/BF03020948","article-title":"Orthotopic liver transplantation for carcinoid tumour metastatic to the liver: anesthetic management.","volume":"47","author":"Claure","year":"2000","journal-title":"Can J Anaesth"},{"key":"R37-5-20210212","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/BF03017444","article-title":"Uneventful spinal anesthesia for a patient with carcinoid syndrome managed with long-acting octreotide.","volume":"49","author":"Orbach-Zinger","year":"2002","journal-title":"Can J Anaesth"},{"key":"R39-5-20210212","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"key":"R40-5-20210212","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/bjc.1992.372","article-title":"Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.","volume":"66","author":"Biesma","year":"1992","journal-title":"Br J Cancer"},{"key":"R41-5-20210212","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00001813-199410000-00001","article-title":"Endocrine tumors of the gastrointestinal tract: systemic treatment.","volume":"5","author":"Oberg","year":"1994","journal-title":"Anticancer Drugs"},{"key":"R42-5-20210212","first-page":"35","article-title":"The action of interferon alpha on human carcinoid tumours.","volume":"3","author":"Oberg","year":"1992","journal-title":"Semin Cancer Biol"},{"key":"R43-5-20210212","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00001813-199603000-00005","article-title":"Long-term results of continuous treatment with recombinant interferon- alpha in patients with metastatic carcinoid tumors-an antiangiogenic effect?","volume":"7","author":"Dirix","year":"1996","journal-title":"Anticancer Drugs"},{"key":"R44-5-20210212","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/0959-8049(92)90060-F","article-title":"Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours.","volume":"10","author":"Janson","year":"1992","journal-title":"Eur J Cancer"},{"key":"R45-5-20210212","first-page":"1265","article-title":"Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.","volume":"71","author":"Smith","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"R46-5-20210212","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3109\/02841869109092426","article-title":"Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha.","volume":"30","author":"Doberauer","year":"1991","journal-title":"Acta Oncol"},{"key":"R47-5-20210212","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3109\/02841869109092413","article-title":"Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide.","volume":"30","author":"Creutzfeldt","year":"1991","journal-title":"Acta Oncol"},{"key":"R48-5-20210212","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1002\/1097-0142(19931115)72:10<3099::AID-CNCR2820721035>3.0.CO;2-4","article-title":"Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.","volume":"72","author":"Bajetta","year":"1993","journal-title":"Cancer"},{"key":"R49-5-20210212","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/02841869309083918","article-title":"Treatment of carcinoid syndrome with recombinant interferon alpha-2a published correction appears in Acta Oncol 32:592;1993.","volume":"32","author":"Di Bartolomeo","year":"1993","journal-title":"Acta Oncol"},{"issue":"suppl 2","key":"R50-5-20210212","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1093\/annonc\/12.suppl_2.S111","article-title":"Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.","volume":"12","author":"Oberg","year":"2001","journal-title":"Ann Oncol"},{"key":"R51-5-20210212","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bpg.2005.02.012","article-title":"Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours.","volume":"19","author":"Shah","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R52-5-20210212","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000085237","article-title":"Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).","volume":"80","author":"Plockinger","year":"2004","journal-title":"Neuroendocrinology"},{"key":"R53-5-20210212","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"R54-5-20210212","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/02841860310010547","article-title":"Carcinoid: a comprehensive review.","volume":"42","author":"Schnirer","year":"2003","journal-title":"Acta Oncol"},{"key":"R55-5-20210212","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","article-title":"Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R56-5-20210212","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","article-title":"Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R57-5-20210212","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/curroncol13020006","article-title":"Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.","volume":"13","author":"Maroun","year":"2006","journal-title":"Curr Oncol"},{"key":"R58-5-20210212","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ejrad.2008.08.008","article-title":"Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol.","volume":"72","author":"Vogl","year":"2009","journal-title":"Eur J Radiol"},{"key":"R59-5-20210212","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00268-001-0015-6","article-title":"Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases.","volume":"25","author":"Siperstein","year":"2001","journal-title":"World J Surg"},{"key":"R60-5-20210212","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.21389","article-title":"Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors.","volume":"104","author":"Gupta","year":"2005","journal-title":"Cancer"},{"key":"R61-5-20210212","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.soc.2008.04.011","article-title":"Development of isolated hepatic perfusion for patients who have unresectable hepatic malignancies.","volume":"17","author":"Jones","year":"2008","journal-title":"Surg Oncol Clin N Am"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006676-201008000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:32:09Z","timestamp":1786041129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006676-201008000-00005"}},"subtitle":["Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum"],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0b013e3181ebb2a5","relation":{},"ISSN":["0885-3177"],"issn-type":[{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}